Scarica l'app Stockscreener
3.74
1.36%
0.05
Precedente Chiudi:
$3.69
Aprire:
$3.7
Volume 24 ore:
8,342
Relative Volume:
0.73
Capitalizzazione di mercato:
$185.40M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-5.0947
EPS:
-0.7341
Flusso di cassa netto:
-
1 W Prestazione:
+0.81%
1M Prestazione:
-7.65%
6M Prestazione:
-5.79%
1 anno Prestazione:
-7.20%
Intervallo 1D:
$3.5834
$3.78
Intervallo di 1 settimana:
$3.5834
$3.81
Portata 52W:
$3.31
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Confronta GNFT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.715 | 185.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.29 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.34 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
625.87 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.81 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.78 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Aggiornamento | Stifel | Hold → Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Underperform |
| 2020-05-13 | Downgrade | Kepler | Buy → Reduce |
| 2020-05-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Reiterato | B. Riley FBR | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-04-24 | Iniziato | SVB Leerink | Outperform |
| 2019-04-22 | Iniziato | Barclays | Overweight |
Mostra tutto
Genfit Adr Borsa (GNFT) Ultime notizie
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis - Finansavisen
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance
Genfit Adr Azioni (GNFT) Dati Finanziari
Non sono disponibili dati finanziari per Genfit Adr (GNFT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):